ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at Proactive's London studio to talk about the latest news on the specialty biopharmaceutical company's p140 platform.
Immupharma recently announced that the US Food and Drug Administration (FDA) has endorsed the company's proposal for a late-stage clinical trial for the treatment of chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disorder.
McCarthy says he's "looking forward with quiet confidence" to getting the next response from the FDA, about its lupus indication.